| Followers | 8 |
| Posts | 2087 |
| Boards Moderated | 0 |
| Alias Born | 07/31/2006 |
Monday, April 27, 2009 9:31:49 PM
Highlights of Today's CEO Interview with Ludlow Capital.
Ludlow Capital Group today posted an 18 1/2 minute interview with NanoViricides CEO Eugene Seymour that was conducted by telephone two days ago on the 25th.
http://www.ludlowcapital.com/reports/bio/nnvc.html
The interview is very interesting relative to the current Swine Flu outbreak, and contains some new information about the company's progress toward licensing of it's Flu and HIV drugs.
I have gone through the 18 minute 30 second interview and summarized what I believe to be several important passages, which I present below.
I also was able to "clean up" some of the telephone hum and balance out some of the audio levels, making the interview much easier to understand and more pleasant to listen to. I've uploaded this cleaned up file to some server space:
http://www.MyDocsOnline.com/pub/DaysOnTheBeach/20090427-NNVC-Ludlow.mp3
Dr. Eugene Seymour, CEO NanoViricides, interviewed by Ludlow Capital Group on 4/15/2009
00:00 -- Intros and background of flu viruses. How viruses enter cells and replicate.
07:00 -- Traditional ways to deal with viral illness 1) with vaccines, and 2) with Tamiflu and similar drugs which are typically administered after symptoms develop and attempt to interfere with viral replication.
09:40 NanoViricides presented Flu-Cide data to a major pharma two months ago, demonstrating "excellent results . . . so much better than Tamiflu". The major pharma expressed an interest in moving forward with Flu-Cide.
11:20 -- How NanoViricides' drugs attack viruses, and why they are broad spectrum.
13:15 -- NanoViricides has been spending it's time on HIV and is "in discussions with multiple pharma companies now about our HIV drug . . . we feel that we can achieve what is called a 'functional cure' [for HIV]". CEO Seymour explained his use of the term "functional cure" and described how it is achieved.
15:10 -- Dr. Seymour gave his opinion on the current Swine Flu outbreak, saying "this could be it [could become a pandemic] . . . showing all the signs of 1917 [the beginnings of the Spanish Flu pandemic] . . . it's a perfect storm". CEO Seymour explained what disease characteristics are most conducive to the creation and sustainability of a pandemic.
16:40 -- "We're rushing as fast as we can to build the manufacturing capability to produce a large amount of our drug . . . when you take it it eradicates the virus in the body".
Thank you to Ludlow Capital Group for conducting this interview!
Best to all.
Ludlow Capital Group today posted an 18 1/2 minute interview with NanoViricides CEO Eugene Seymour that was conducted by telephone two days ago on the 25th.
http://www.ludlowcapital.com/reports/bio/nnvc.html
The interview is very interesting relative to the current Swine Flu outbreak, and contains some new information about the company's progress toward licensing of it's Flu and HIV drugs.
I have gone through the 18 minute 30 second interview and summarized what I believe to be several important passages, which I present below.
I also was able to "clean up" some of the telephone hum and balance out some of the audio levels, making the interview much easier to understand and more pleasant to listen to. I've uploaded this cleaned up file to some server space:
http://www.MyDocsOnline.com/pub/DaysOnTheBeach/20090427-NNVC-Ludlow.mp3
Dr. Eugene Seymour, CEO NanoViricides, interviewed by Ludlow Capital Group on 4/15/2009
00:00 -- Intros and background of flu viruses. How viruses enter cells and replicate.
07:00 -- Traditional ways to deal with viral illness 1) with vaccines, and 2) with Tamiflu and similar drugs which are typically administered after symptoms develop and attempt to interfere with viral replication.
09:40 NanoViricides presented Flu-Cide data to a major pharma two months ago, demonstrating "excellent results . . . so much better than Tamiflu". The major pharma expressed an interest in moving forward with Flu-Cide.
11:20 -- How NanoViricides' drugs attack viruses, and why they are broad spectrum.
13:15 -- NanoViricides has been spending it's time on HIV and is "in discussions with multiple pharma companies now about our HIV drug . . . we feel that we can achieve what is called a 'functional cure' [for HIV]". CEO Seymour explained his use of the term "functional cure" and described how it is achieved.
15:10 -- Dr. Seymour gave his opinion on the current Swine Flu outbreak, saying "this could be it [could become a pandemic] . . . showing all the signs of 1917 [the beginnings of the Spanish Flu pandemic] . . . it's a perfect storm". CEO Seymour explained what disease characteristics are most conducive to the creation and sustainability of a pandemic.
16:40 -- "We're rushing as fast as we can to build the manufacturing capability to produce a large amount of our drug . . . when you take it it eradicates the virus in the body".
Thank you to Ludlow Capital Group for conducting this interview!
Best to all.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
